Kim Pabst

Physician and Scientist at the Department of Nuclear Medicine, University Hospital Essen, Germany, with interest in FAP-Theranostic and thyroid cancer

[Kim Pabst @K_M_Pabst]

Thank you for the opportunity to present "FAPI imaging and radioligand therapy" in Davos this year. It was a great pleasure to participate.
#SCR23 #SwissCongressofRadiology

[Swiss Congress of Radiology @info_scr]

🎢Buckle up for „𝐅𝐀𝐏𝐈, 𝐫𝐞𝐚𝐝𝐲 𝐟𝐨𝐫 𝐩𝐫𝐢𝐦𝐞 𝐭𝐢𝐦𝐞?“ with 𝐀. 𝐉𝐨𝐡𝐚𝐲𝐞𝐦, 𝐊. 𝐏𝐚𝐛𝐬𝐭 and 𝐀. 𝐀𝐭𝐳𝐢𝐧𝐠𝐞𝐫 on 𝐅𝐫𝐢𝐝𝐚𝐲, June 23rd, from 09:30 to 10:45!

✨ More info and registration on our website: https://t.co/1Ed5AgKfOj

#SCR23 #radiology

[JNM @JournalofNucMed]

The largest FAP-targeted prospective FAPI registry study with a head-to-head comparison of tumor uptake in ⁶⁸Ga-FAPI and ¹⁸F-FDG PET, as well as FAP immunohistochemistry. https://t.co/cZ6fLQYFiU

#NuclearMedicine #Cancer #MedicalImaging @ProfKHerrmann

[Sam Nordic @sam_nordic]

Listen to today's episode here: https://t.co/NAbkjJnfuS

[Sam Nordic @sam_nordic]

What are the world’s leading experts saying about FAPI? What possibilities are created, & can it be used in the diagnosis & treatment of different cancer types? Today's episode of Theragnostic Talks is now out. Live from EANM'22 Congress in Barcelona.

[JNM @JournalofNucMed]

¹⁷⁷Lu-PSMA-617 initiation at no more than eight weeks after ²²³Ra in patients with progressive bone-metastatic disease was effective, with acceptable safety. https://t.co/nN7VUgZJQW

#RPTherapy #NuclearMedicine #ProstateCancer #MCRPC @Dr_K_Rahbar @sartor_oliver